¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

À̼¶À¯¼Ò¿øÇ÷Áõ(¼±Ãµ)(Dysfibrinogenaemia(congenital))

ÃßõÇϱâ
Áúº´Á¤º¸ À̹øÁÖ BEST
 

ÁúȯÁÖ¿äÁ¤º¸

  • °ü·ÃÁúȯ¸í :
  • ¿µÇâºÎÀ§ : ü³»:Ç÷°ü(Ç÷¾×)
  • Áõ»ó : ÃâÇ÷, Ç÷Àü
  • ¿øÀÎ : chainÀÇ 275R ¾Æ¹Ì³ë»ê C,H,S µîÀ¸·Î ġȯ, ¸íÈ®ÇÏÁö ¾ÊÀ½
  • Áø´Ü : ÀÀ°í ´Ü¹éÀ» ÀÌ¿ëÇÑ ¹æ¹ý°ú ¸é¿ªÇÐÀû ¹æ¹ýÀÇ ºÒÀÏÄ¡ ¼Ò°ß
  • Ä¡·á : ´ëºÎºÐÀÇ ¼±Ãµ¼º ÀÌ»ó¼¶À¯¼Ò¿øÇ÷ÁõÀº ¹«Áõ»óÀ¸·Î Ä¡·á°¡ ÇÊ¿äÇÏÁö ¾ÊÀ¸³ª ±Þ¼º ÃâÇ÷ÀÌ ÀÖÀ» ¶§ ¼¶À¯¼Ò¿ø º¸ÃæÀÌ ÇÊ¿äÇÏ°í, ÃâÇ÷ °ú°Å·ÂÀÌ ÀÖÀ¸¸é¼­ ¼ö¼úÀ̳ª óÁö°¡ ÇÊ¿äÇÒ ¶§ ¿¹¹æÀû º¸ÃâÀÌ ÇÊ¿ä
  • »êÁ¤Æ¯·ÊÄÚµå : V009
  • ÀÇ·áºñÁö¿ø : Áö¿ø

¥°.°³¿ä

ÀÌ»ó¼¶À¯¼Ò¿øÇ÷ÁõÀ̶õ ¼¶À¯¼Ò¿ø(fibrinogen)ÀÇ ±¸Á¶Àû ÀÌ»óÀÌ À¯ÀüµÇ¾î Ç÷ÀüÁõ ¶Ç´Â ÃâÇ÷ÁõÀ» À¯¹ßÇÏ´Â ÁúȯÀ¸·Î ¼±Ãµ¼º ¶Ç´Â ÈÄõ¼ºÀ¸·Î ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼±Ãµ¼º ÀÌ»ó¼¶À¯¼Ò¿øÇ÷ÁõÀº Áö±Ý±îÁö 350¿¹ÀÇ ºñÇ÷¿¬ °¡Á·¿¡¼­ ¹ß»ýÇÏ¿´°í ÀÌÁß ±¸Á¶Àû ÀÌ»óÀÌ Áõ¸íµÈ °æ¿ì°¡ 170¿¹ÀÇ °¡Á·¿¡¼­ º¸°íµÇ¾ú½À´Ï´Ù. ´ëºÎºÐÀÇ ±¸Á¶Àû ÀÌ»óÀº Á¡ µ¹¿¬º¯ÀÌ¿¡ ÀÇÇØ Àü»çµÈ ¼¶À¯¼Ò¿ø ºÐÀÚÀÇ ´ÜÀÏ ¾Æ¹Ì³ë»ê ġȯ¿¡ ÀÇÇϸç ÇöÀç±îÁö ±¹³»¿¡¼­´Â 2¿¹°¡ º¸°íµÇ¾ú½À´Ï´Ù.

ÈÄõ¼ºÀÇ °¡Àå ÈçÇÑ ¿øÀÎÀº °£ÁúȯÀÌ µ¿¹ÝµÈ °æ¿ì¿¡ ¹ßº´ÇÕ´Ï´Ù.

¥±.Áõ»ó

¼±Ãµ¼º ÀÌ»ó¼¶À¯¼Ò¿øÇ÷ÁõÀÇ ¾à 55%´Â ¹«Áõ»óÀ̾ú°í, 25%´Â ÃâÇ÷ °æÇ⸸ ÀÖ¾ú°í, 20%´Â Ç÷ÀüÁõÀÌ ÀÖ¾úÀ¸¸ç ÀÌÁß ¾à 2%´Â Ç÷ÀüÁõ°ú ÃâÇ÷ÀÌ µ¿¹ÝµÇ¾î ³ªÅ¸³µ½À´Ï´Ù. ÀÌ»ó¼¶À¯¼Ò¿øÇ÷ÁõÀº µå¹°°Ô â»óÄ¡À¯ÀÇ Áö¿¬°ú ÀÚ¿¬À¯»êÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç Ç÷Àü¼º °æÇâÀ» º¸¿´´ø ȯÀڵ鿡¼­ ƯÈ÷ ÀӽŰú °ü·ÃµÈ Ç÷Àü¼º ÇÕº´ÁõÀ¸·Î ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõÀ̳ª Æó»öÀüÁõÀÌ µ¿¹ÝµÉ ¼ö ÀÖ½À´Ï´Ù. ¿©¼º ȯÀÚÀÇ °æ¿ì Ãâ»ê ÈÄ °ú´Ù ÃâÇ÷ÀÌ Ã¹ Áõ»óÀÏ ¼ö ÀÖÀ¸¸ç ¸î¸î ȯÀÚÀÇ °æ¿ì´Â â»óÄ¡À¯ Áö¿¬ ¹× â»óÀÇ ¹ú¾îÁüÀÌ °¡Àå ½ÉÇÑ ÀÌ»ó¼Ò°ß ÀÏ ¼ö ÀÖ½À´Ï´Ù.

¥².¿øÀÎ

¹Ýº¹µÇ´Â Ç÷ÀüÁõÀ¸·Î Áõ»óÀÌ ¹ßÇöµÈ ÀÌ»ó¼¶À¯¼Ò¿øÁõÀº Ç÷ÀüÁõÀÇ ºÐÀÚ±¸Á¶ÇÐÀû ¿øÀÎÀÌ ¹àÇôÁø °Íµµ ÀÖÁö¸¸, ¾ÆÁ÷ ±× ¿øÀÎÀ» ÃæºÐÈ÷ ±Ô¸íÇÏÁö ¸øÇÑ °æ¿ìµµ ÈçÇÕ´Ï´Ù.

ÀÌ»ó¼¶À¯¼Ò¿øÇ÷Áõ¿¡¼­ Ç÷ÀüÁõ À§ÇèÀÌ Áõ°¡µÇ´Â ±âÀüÀº ¾ÆÁ÷±îÁö ¸íÈ®ÇÏ°Ô ¹àÇôÁöÁö ¾Ê¾ÒÀ¸³ª ƯÀÌ ¼¶À¯¼Ò¿ø °áÇÔÀÇ Æ¯¼º¿¡ ÀÇÇÑ °ÍÀ¸·Î º¸À̸ç ÀÌ·ÐÀûÀ¸·Î ÀÀ°í Çü¼ºÀÇ Áõ°¡ ¶Ç´Â ¼¶À¯¼Ò¿ëÇØÀÇ Àå¾Ö·Î ÀÎÇØ °ú´ÙÇÑ Ç÷ÀüÁõÀÌ À¯¹ßµÇ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¥³.Áø´Ü

¼¶À¯¼Ò Çü¼º¿¡ ÇʼöÀûÀÎ ¼¶À¯¼Ò¿øÀÇ ±â´ÉÀû Àå¾Ö·Î Ç÷¾× ÀÀ°í°Ë»çÀÎ ÇÁ·ÎÆ®·Òºó ½Ã°£(prothrombin time, PT), È°¼ºÈ­ ºÎºÐÆ®·Òº¸Çöó½ºÆ¾½Ã°£(activated partial thromboplastin time, aPTT), Æ®·Òºó½Ã°£(thrombin time, TT)ÀÇ ¿¬ÀåÀÌ ³ªÅ¸³¯ ¼ö ÀÖ½À´Ï´Ù. PT°¡ aPTT º¸´Ù ¹Î°¨ÇÏ°í TT°¡ ´õ ¹Î°¨Çϸç ƯÀ̼º ÀÖ´Â °Ë»çÀÔ´Ï´Ù. ÀϺΠȯÀÚ¿¡¼­´Â TTÀÇ ½ÉÇÑ ¿¬ÀåÀ¸·Î ÀÎÇØ Ç÷¾× ÀÀ°í°¡ Àý´ë ÀÌ·ç¾îÁöÁö ¾Ê´Â °æ¿ìµµ Àִµ¥ Á¤»ó Ç÷ÀåÀ̳ª ³óÃ༶À¯¼Ò¿øÀ» Åõ¿©Çϸé ÀÌ·± °Ë»ç°¡ Á¤»óÈ­µÉ ¼ö ÀÖ½À´Ï´Ù.

´ëºÎºÐÀÇ °æ¿ì ¸é¿ªÇÐÀûÀ¸·Î ¼¶À¯¼Ò¿ø ³óµµ¸¦ ÃøÁ¤ÇÒ °æ¿ì Á¤»óÀ¸·Î ÃøÁ¤µÇ¸ç, ÀÀ°í ´Ü¹éÀ» ÀÌ¿ëÇÑ °Ë»ç¿Í ¸é¿ªÇÐÀû °Ë»çÀÇ ºÒÀÏÄ¡ ¼Ò°ßÀº ÀÌ»ó¼¶À¯¼Ò¿øÇ÷Áõ Áø´Ü¿¡ Ư¡Àû ¼Ò°ßÀÔ´Ï´Ù. ÀÌ»ó¼¶À¯¼Ò¿øÇ÷ÁõÀÇ Áø´ÜÀº ÀÓ»óÀû Àǽɰú ÀûÀýÇÑ ÀÌ»ó´Ü¹éÁú¿¡ ´ëÇÑ °Ë»ç ¶Ç´Â DNA ºÐ¼®À» ÅëÇÏ¿© À¯ÀüÀÚ °áÇÔÀ» Áõ¸íÇÔÀ¸·Î½á Áø´ÜµÉ ¼ö ÀÖ½À´Ï´Ù.

»êÁ¤Æ¯·Ê Áø´Ü±âÁØ

1. mutations in the coding region of the fibrinogen FGA, FGB, or FGG genes
2. autosomal dominant
3. silent(55%), hemorrhagic(25%), thrombotic diathesis(10-20%)
1) Thrombotic variants
: thrombophilia, Venous thrombosis of the lower extremity dominates, arterial thrombosis or both venous/arterial thrombosis, postpartum thrombosis, spontaneous abortions
: Fibrinogen concentrations were normal or low
2) Hemorrhagic variants
: Most bleeding manifestations are moderate, but some can be severe
: fibrinogen levels < 50-100 mg/dL - higher frequency of bleeding complications
: epistaxis, menorrhagia, easy bruisability, soft tissue hemorrhage, postoperative bleeding, antepartum/postpartum bleeding, hematomas/hemarthrosis
: Bleeding often manifests after trauma, surgery, or during the postpartum period
3) Silent mutations: ¹«Áõ»ó
4) ±âŸ: renal amyloidosis, renal failure, hepatic storage disease, delayed wound healing and/or wound dehiscence
4. Áø´Ü
1) Global screening tests: whole blood clotting time, PT, aPTT
2) Initial screening tests: immunologic(antigenic)/clotting(functional) fibrinogen concentration, thrombin time(TT), reptilase time(RT)
- TT/RT: ¿¬Àå
- functional fibrinogen: °¨¼Ò ȤÀº Á¤»ó
- immunologic fibrinogen concentration: Á¤»ó ȤÀº Áõ°¡

*Áø´Ü¹æ¹ý : Ư¼ö »ýÈ­ÇÐ/¸é¿ªÇÐ °Ë»ç, µµ¸»/¹è¾ç°Ë»ç

¥´.Ä¡·á

´ëºÎºÐÀÇ ¼±Ãµ¼º ÀÌ»ó¼¶À¯¼Ò¿øÇ÷ÁõÀº ¹«Áõ»óÀ¸·Î Ä¡·á°¡ ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù. ÇÏÁö¸¸ ±Þ¼º ÃâÇ÷ÀÌ ÀÖÀ» °æ¿ì¿¡´Â ¼¶À¯¼Ò¿ø º¸ÃæÀÌ ÇÊ¿äÇÏ°í, ÃâÇ÷ °ú°Å·ÂÀÌ ÀÖÀ¸¸é¼­ ¼ö¼úÀ̳ª óġ¸¦ ÇؾßÇÏ´Â °æ¿ì ¿¹¹æÀû º¸ÃæÀÌ ÇÊ¿äÇÕ´Ï´Ù.

Ç÷ÀüÁõÀÌ µ¿¹ÝµÈ °æ¿ì¿¡ Ç×ÀÀ°íÁ¦ »ç¿ëÀÌ ±ÇÀåµÇÁö¸¸ »ç¿ë±â°£¿¡ ´ëÇÑ ÁöħÀº È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¸ç ÃâÇ÷ÀÇ À§Çèµµ¸¦ °í·ÁÇÏ¿© »ç¿ë ±â°£À» °áÁ¤ÇØ¾ß ÇÕ´Ï´Ù.

ÀæÀº ÀÚ¿¬À¯»êÀ» º¸ÀÌ´Â °æ¿ì¿¡´Â ¼¶À¯¼Ò¿øÀ» µ¿°áħÀüÁ¦Á¦ ÇüÅ·ΠÁö¼ÓÀû º¸ÃæÀ» ÇÔÀ¸·Î¼­ ÀÓ½ÅÀ» À¯ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù.

[Âü°í¹®Çå ¹× »çÀÌÆ®]

HEMATOLOGY, 4TH Ed,: William J. Williams, et al., Editors; McGraw-Hill, Inc. Pp. 1474-75.
Ç÷¾×ÇÐ, ´ëÇÑÇ÷¾×ÇÐȸ, ÀÌÆÛºí¸¯, 2006
Park E, Park G, Park R, Kim HJ, Lee SJ, et al. Fibrinogen Yecheon: Congenital Dysfibrinogenemia with Gamma Methionine-310 to Threonine Substitution. J Korean Med Sci. 2009 Dec;24(6):1203-1206. English. doi: 10.3346/jkms.2009.24.6.1203.
Kim I, Park S, Kwon S, Chung I, Lee S. Biochemical Characteristics of Dysfunctional Fibrinogen Found in Korea. Korean J Hematol. 2005 Mar;40(1):34-40. Korean. doi: 10.5045/kjh.2005.40.1.34.
http://www.rarediseases.org


Ãâó: ±¹°¡°Ç°­Á¤º¸Æ÷ÅÐ
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" À̼¶À¯¼Ò¿øÇ÷Áõ(¼±Ãµ)(Dysfibrinogenaemia(congenital))""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û °Ô¸£½ºÆ®¸¸ ½´Åõ·ÎÀ̽½·¯ »þÀ×Ä¿ º´
´ÙÀ½±Û Æç°Å-ÈÞ¿¡ ÀÌ»óÁõ(Pelger-Huet anomaly)
¹øÈ£
Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
5140
 
À¯ÀüÀÚ °Ë»ç ¹«·áüÇè´Ü ¸ðÁý
1 2,688 2020-09-18
5139
 
Äڷγª¹ÙÀÌ·¯½º°¨¿°Áõ-19(COVID-19) Á¤º¸
0 5,315 2020-03-28
5138
 
Ä¡¸Å Ä¡·á
4 5,871 2017-05-04
5137
 
ÀڱðæºÎ¾Ï ±âŸÁ¤º¸
0 5,158 2017-05-04
5136
 
ÀڱðæºÎ¾Ï ´ë»óº° ¸ÂÃãÁ¤º¸
0 5,268 2017-05-04
5135
 
ÀڱðæºÎ¾Ï Áõ»ó
1 12,934 2017-05-04
5134
 
ÀڱðæºÎ¾Ï À§Çè¿äÀÎ
0 5,368 2017-05-04
5133
 
ÀڱðæºÎ¾Ï Á¤ÀÇ
0 4,467 2017-05-04
5132
 
ÀڱðæºÎ¾Ï ¿¹¹æ
0 4,606 2017-05-04
5131
 
ÂêÂê°¡¹«½Ãº´ ±âŸÁ¤º¸
0 3,747 2017-05-04
5130
 
ÂêÂê°¡¹«½Ãº´ ¿¹¹æ
0 4,117 2017-05-04
5129
 
ÂêÂê°¡¹«½Ãº´ ¿øÀÎ
0 4,093 2017-05-04
5128
 
³úÁ¹Áß ±âŸÁ¤º¸
0 4,219 2017-05-04
5127
 
°©»ó¼±±â´ÉÇ×ÁøÁõ ȯÀÚµéÀÌ ÀÚÁÖÇÏ´ÂÁú¹®
0 7,039 2017-05-04
5126
 
Á¶±â»ç¸Á Èí¿¬ ¹ÌÄ¡´Â ¿µÇâ
0 4,712 2017-05-03
5125
 
ÇǺγëÈ­ ¿øÀÎ Èí¿¬
0 5,552 2017-05-03
5124
 
¹ß±âºÎÀü ¿øÀÎ Èí¿¬
0 5,487 2017-05-03
5123
 
ÀÓ½ÅÁß Èí¿¬ À¯»ê ±âÇüÀÇÃâ»ê ¿øÀÎ
0 5,367 2017-05-03
5122
 
ºÎ¸ðÈí¿¬ ÀÚ³à°Ç°­ À§Çù
0 4,154 2017-05-03
5121
 
³úÁ¹Á߹߻ý ¿øÀÎ Èí¿¬
1 4,201 2017-05-03
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷